ScreenerHero
RKVRakovina Therapeutics Inc.
TSXV · CA · Healthcare · Biotechnology · rakovinatherapeutics.com
0.1500CAD+13.33%Mkt Cap: 3.02M $P/E: —

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD
HeadlineSourceTime
Older
AI Chips Today - AI Boosts Cancer Drug Discovery Through Innovative Techniques

Rakovina Therapeutics Inc. has presented promising data at the 2025 Society for Neuro-Oncology Annual Meeting, demonstrating advancements in their AI-derived PARP1 inhibitor program. Utilizing AI methods such as Deep Docking™ and generative AI, the company has been able to effectively screen large chemical libraries, resulting in the discovery of novel, CNS-penetrant, PARP1-selective small molecules. These compounds have undergone biochemical evaluations, with a subset showing favorable...

Simply Wall St.
Rakovina Therapeutics Presents Poster at Cancer Therapeutics Conf in Boston

Rakovina Therapeutics (RKV.V) Monday said it has presented new data at an international conference o

MMT Newswires